Related Experiment Video

Updated: Jun 3, 2026

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature

J PosthumaDeBoer1, M A Witlox, G J L Kaspers

  • 1Department of Orthopaedic Surgery, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

Clinical & Experimental Metastasis
|April 5, 2011
PubMed

Insights

Treating metastatic osteosarcoma (OS) is difficult because current therapies target primary tumors, not metastases. Understanding metastatic OS cell biology can lead to new treatments that improve patient outcomes.

Area of Science:

  • Oncology
  • Cancer Metastasis Research

Background:

  • Metastatic osteosarcoma (OS) presents significant treatment challenges in oncology.
  • Current therapies primarily focus on the primary tumor, showing limited efficacy against metastatic disease.

Purpose of the Study:

  • To review the biological characteristics and behavior of metastatic OS cells.
  • To explore preclinical and clinical strategies targeting OS metastasis.
  • To inform the development of metastasis-directed treatments for OS.

Main Methods:

  • Literature review of biological changes in metastatic OS cells.
  • Analysis of preclinical and clinical studies targeting OS metastasis.
  • Synthesis of findings to propose innovative treatment strategies.

Main Results:

  • Metastatic OS cells possess unique features contributing to therapeutic resistance.
  • Targeting these specific features holds potential for enhancing current treatment efficacy.
  • Various preclinical and clinical efforts are underway to combat OS metastasis.

Conclusions:

  • A deeper understanding of metastatic OS cell biology is crucial for developing effective treatments.
  • Metastasis-directed therapies are essential for improving outcomes in patients with metastatic osteosarcoma.
  • Future research should focus on targeting the distinct biological aspects of OS metastasis.

More Related Videos

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...